John V. Oyler, Co-Founder, Chairman & CEOAs the oncology landscape expands with scientific advancements, the reality remains: high costs, logistical hurdles, and inequities in healthcare delivery delay life-saving therapies from reaching large segments of the global population. The company is here to change that equation.
Founded in 2010, BeOne has embraced an identity that mirrors its mission. Its name reflects a rallying cry, to BeOne to end cancer. The company is creating the world’s next-generation cancer treatments through relentless innovation and a sustainable business model that leverages cost and time efficiencies to enable better access for patients around the world. With the motto “Cancer has no borders–and neither do we,” the company is pioneering a new era of inclusive, agile and sustainable cancer care - one where geographic borders, socioeconomic status, and outdated clinical trial models no longer dictate a patient’s access to care. For John V. Oyler, co-founder, chairman, and CEO, the company’s strategy is rooted in access and acceleration.
“Innovation loses its meaning if it only serves a few. That’s why we built BeOne to do more than discover – we built it to deliver everywhere,” says John V. Oyler, Co-Founder, Chairman & CEO.
Building a Company for Global Impact
For decades, oncology drug development has been structurally biased toward the wealthiest nations— concentrating clinical trials and commercial launches in the U.S., Europe, and Japan. These markets represent just one-sixth of the world’s eligible cancer patients. The result: a system where the vast majority of people—five-sixths of the global population—are left waiting years to access the most advanced treatments, if they gain access at all. It’s a model driven by the need to recover high development costs in high-return markets.
Oyler saw this not only as a moral failure but as a systemic flaw—an entrenched inefficiency that limits both access and innovation. He understood that the rising cost of developing oncology medicines—75 percent of which is spent on clinical trials—was reinforcing global health inequity. As long as trials were concentrated in the U.S., EU, and Japan, companies would be compelled to prioritize those markets alone, entrenching the imbalance.
But Oyler also saw a transformative opportunity: by shifting where and how trials are conducted, it was possible to change the cost structure of drug development itself. BeOne believed in building an inclusive clinical trial model that expands beyond traditional geographies to include countries like South Korea, Poland, and Brazil. It wasn’t just about including more countries—it was about building a new operating model that unlocked advantages in cost, speed, and quality, while simultaneously laying the foundation for sustainable access and commercialization in these same markets.
This insight led to the creation of a globally inclusive R&D model that is redefining the economics and timelines of oncology drug development. The company’s clinical development team now executes the majority of its trials internally, leveraging its integrated infrastructure across six continents. This end-to-end capability—spanning clinical, regulatory, and commercial—means BeOne can transition seamlessly from trial execution to patient access, achieving greater global reach with a significantly more efficient model.
In doing so, BeOne isn’t just expanding the geographic footprint of its trials. With a “Fast to Proof of Concept” model, the company accelerates early-stage development and regulatory approval timelines, allowing promising therapies to reach patients sooner. It’s reimagining what global access to innovation can look like—and proving that broader reach and greater efficiency can go hand in hand in drug development. One of the clearest demonstrations of this strategy is BRUKINSA (zanubrutinib), BeOne’s BTK inhibitor.
-
Innovation loses its meaning if it only serves a few. That’s why we built BeOne to do more than discover – we built it to deliver everywhere
In doing so, BeOne isn’t just expanding the geographic footprint of its trials. With a “Fast to Proof of Concept” model, the company accelerates early-stage development and regulatory approval timelines, allowing promising therapies to reach patients sooner. It’s reimagining what global access to innovation can look like—and proving that broader reach and greater efficiency can go hand in hand in drug development. One of the clearest demonstrations of this strategy is BRUKINSA (zanubrutinib), BeOne’s BTK inhibitor.
Approved in over 75 markets in at least one indication, BRUKINSA has rapidly become a leading choice in the U.S. BeOne’s ability to accelerate enrollment through an expansive network of global sites enabled it to complete a Phase 3 trial in just 14 months—an extraordinary benchmark in oncology. Today, BRUKINSA has the broadest global label of any BTK inhibitor with five indications. The company’s immunotherapy, TEVIMBRA (tislelizumab), is approved in more than 45 countries.
The company remains steadfast in advancing its early-stage, prolific solid tumor pipeline, targeting high-burden cancers such as breast, lung, and gastrointestinal cancers.
BeOne has planned trials or enrolled patients in clinical trials in more than 45 countries and regions, including Australia, Brazil, the European Union, South Africa, Thailand, and the United States.
Transforming Cancer Care—One Patient, One Breakthrough at a Time
BeOne’s clinical development model is reshaping how cancer treatments are designed and delivered. At BeOne, patients are at the heart of its mission. Improving patient access is one goal in the company’s effort to positively impact the lives of cancer patients and their caregivers. BeOne knows that actively engaging with patients throughout clinical development ensures their therapies meet patient needs, which ultimately supports better outcomes. BeOne asks patients for their input from the earliest R&D stages through trial development. Through the company’s early patient engagement work within Global Medical Affairs, BeOne facilitates and manages patient insight gathering across clinical trials to support study teams as they work to develop trials that take into consideration the needs of patients. This important collaboration, utilizing measurable success metrics to ensure program accountability, reflects and integrates both patient and caregiver insights into BeOne’s R&D planning. The team also works with internal and external experts to develop an individualized patient engagement strategy to ensure that patients are aware of clinical trials as part of their journey with cancer. The company is committed to a drug development approach and commercialization strategy that accurately reflects patients’ true lived experiences and expectations—a central component of providing patients with access to meaningful treatment.
BeOne’s partnerships with patient advocacy organizations also play a critical role in bridging gaps in education and access, ensuring that patients and caregivers are better equipped to navigate their treatment journey.
One example is their collaboration with CLL Society on Test Before Treat™, a nationwide awareness campaign focused on the importance of biomarker testing in chronic lymphocytic leukemia (CLL). Designed to reach both patients and healthcare providers, the initiative encourages testing before starting treatment and retesting at each subsequent line of therapy. Approximately half of CLL patients carry high-risk genetic markers that may limit the effectiveness of certain therapies, including chemotherapy. Identifying these markers early—and continuing to test over time—can significantly influence treatment decisions and improve outcomes, including through the use of targeted therapies. Anchored by real patient experiences, the campaign helps drive more informed, personalized care across the CLL community.
End-to-End Integration for Speed, Scale, and Resilience
BeOne’s commitment to global inclusion extends well beyond clinical trials. By investing in end-to-end control of the value chain—from discovery and development to manufacturing and commercialization—the company has crafted an ecosystem built for speed, scale, and access.
A major milestone in this journey was the opening of the company’s flagship U.S. facility in Hopewell, New Jersey, in 2024. Situated on a 42-acre site at the Princeton West Innovation Campus, the center represents an $800 million investment in the future of biologics manufacturing and clinical research. It adds 400,000 square feet of scalable capacity and creates hundreds of high-tech jobs, solidifying the company’s presence in the U.S. and complementing its already formidable global infrastructure.
The Hopewell facility is a strategic node in a decentralized, resilient global network. BeOne’s end-to-end capabilities allow the company to pivot quickly, maintain quality across geographies, and reduce its exposure to global supply chain disruptions. While the industry is still reeling from COVID-era shocks, this operational resilience adds a competitive advantage of the highest order.
As it scales, the company continues to strengthen its strong foundation through investing in its talented workforce, leveraging operational efficiencies, and ensuring appropriate governance is maintained through the value chain. In line with putting patients first, BeOne prioritizes building operational, geographical and environmental resilience across the entire global footprint, safeguarding patient access to cancer care.
A New Company Model Built for Purpose
To date, BeOne has brought treatments to more than 1.7 million patients worldwide, including 200,000 through BRUKINSA and over 1.5 million through TEVIMBRA. But this is just the beginning. The company boasts one of the industry’s most prolific oncology pipelines, aimed at tackling high-burden cancers such as lung, breast, and gastrointestinal tumors.
Its strategic investments in people, technology, and geography reflect a long-haul vision—one where sustainability meets scale, and where innovation is only meaningful if it’s universally accessible.
The company is not only rewriting the oncology playbook; it is redefining the role of a biotech company in the 21st century. It merges world-class science with a humanitarian ethos, operational excellence, and moral clarity. It’s a company built for impact, measured not just in drug approvals but in lives improved, access expanded, and systems transformed.
“We’re not just trying to make great medicines,” Oyler says. “We’re trying to redesign the whole system so that innovation doesn’t stop at borders.”
The goal is ambitious. And if BeOne’s track record is any indication, it’s a bet worth watching.
Choosing a Gold-Standard Oncology Partner
Cancer programs now operate at the intersection of scientific innovation, access demands and financial discipline. For executives evaluating next-generation oncology partners, the key question is no longer simply whether a company can develop promising science. The more important issue is whether that science can move efficiently through development, manufacturing, evidence generation and market access in a way that broadens patient reach without creating unnecessary cost or delay.
The pressure is particularly intense across biotechnology because oncology innovation has become more complex while payer, physician and patient expectations continue tightening. A strong molecule alone is not enough. Organizations must evaluate whether a partner can enroll diverse patient populations, manage trial timelines, maintain product quality and support adoption across markets with very different reimbursement systems, infrastructure limitations and clinical practices. The strongest oncology companies treat development speed and patient access as connected outcomes shaped by operational design rather than separate objectives.
Scale by itself should not be viewed as a competitive advantage. What matters is whether scale is supported by disciplined coordination across research, clinical development, manufacturing and commercialization. Oncology programs frequently lose momentum when sponsors rely too heavily on fragmented external networks, compete for limited trial populations or delay supply planning until demand is already established. Stronger models extend beyond major research centers, bring clinical trial activity closer to underserved populations and maintain sufficient internal control to protect quality, timing and cost management. As global cancer burden rises unevenly across regions, development strategy increasingly determines whether innovation widens access gaps or helps reduce the time between clinical evidence and patient availability.
Pipeline breadth also deserves careful scrutiny. A broad portfolio may signal ambition, but it can dilute focus unless organized around coherent scientific platforms and clearly defined patient needs. Strong oncology partners demonstrate how hematology, solid tumors, immuno-oncology and biomarker-driven care connect within a larger development strategy. They also support physicians with evidence that improves treatment decisions rather than relying solely on product availability. In diseases such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), that means supporting testing, risk stratification and physician education around treatment selection because patient access without clinical clarity still limits outcomes.
Manufacturing and supply capability have become equally important. Global oncology organizations must manage demand fluctuations, regional disruptions and evolving therapeutic modalities while maintaining quality standards trusted by regulators, clinicians and health systems. Manufacturing infrastructure, late-stage development capabilities and local market presence should function as integrated strengths rather than isolated assets. Companies that shorten the distance between scientific discovery, production and patient availability create a more reliable path from innovation to real-world clinical use.
BeOne Medicines merits attention for organizations seeking an oncology partner built around that integrated approach. Its strengths include BRUKINSA in hematologic malignancies, TEVIMBRA as a PD-1 antibody for solid tumor treatment, a broad hematology and solid tumor pipeline, internal clinical development capabilities, global trial reach and end-to-end manufacturing across small molecules, biologics and antibody-drug conjugates. Its U.S. operations in Hopewell, New Jersey, further strengthen biologics manufacturing and clinical R&D capacity, while myBeOne Support provides eligible BRUKINSA patients with access assistance. For organizations prioritizing scientific depth, development speed, supply coordination and broader treatment access, BeOne Medicines represents a compelling option.
...Read more
Next-generation Oncology Info
Q1
Why is BeOne Medicines recognized among Top Oncology Biotechnology Companies?
BeOne Medicines is recognized in Oncology Biotechnology Companies for its globally integrated approach to cancer drug discovery and development. It focuses on creating innovative therapies across hematology and solid tumors while simultaneously improving global access to treatment. The company has built a strong oncology pipeline and commercial portfolio that includes BRUKINSA and TEVIMBRA, positioning it as a key player in next-generation cancer therapeutics. Its recognition is also driven by its ability to combine scientific innovation with large-scale global clinical execution.
Q2
What differentiates BeOne Medicines in Oncology Biotechnology Companies?
A defining differentiator for BeOne Medicines in Oncology Biotechnology Companies is its globalized R&D and clinical development model. Instead of concentrating trials in limited regions, it runs studies across more than 45 countries, improving speed, diversity and access. This structure allows faster proof-of-concept generation and more efficient regulatory pathways. The company also integrates discovery, manufacturing and commercialization within one system, reducing fragmentation across the drug development lifecycle.
Q3
How does BeOne Medicines accelerate oncology drug development?
BeOne Medicines accelerates development through Oncology Biotechnology Companies–style integrated execution, combining in-house clinical operations, global trial networks and streamlined regulatory coordination. Its “Fast to Proof of Concept” model helps shorten early development timelines while maintaining scientific rigor. This approach has enabled rapid advancement of therapies like BRUKINSA, which achieved broad global approvals across multiple indications in a compressed timeframe.
Q4
How do Oncology Biotechnology Companies like BeOne Medicines improve patient access to therapies?
Oncology Biotechnology Companies such as BeOne Medicines improve patient access by redesigning how clinical trials and commercialization strategies are executed. BeOne emphasizes conducting trials in diverse geographies, including emerging markets, to reduce delays in access to innovative treatments. It also focuses on scalable manufacturing and global distribution strategies that help ensure therapies reach patients beyond traditional high-income regions.
Q5
What role does innovation play in BeOne Medicines’ oncology strategy?
Innovation is central to Oncology Biotechnology Companies like BeOne Medicines, particularly in its multi-target oncology pipeline and biologics development. The company advances therapies across BTK inhibition, immunotherapy and solid tumor research while investing in next-generation molecules. Its pipeline includes multiple clinical-stage candidates designed to address high-burden cancers such as lung, breast and gastrointestinal tumors, reflecting a strong innovation-driven growth model.
Q6
Why are Oncology Biotechnology Companies like BeOne Medicines important in modern cancer treatment?
Oncology Biotechnology Companies like BeOne Medicines are critical because they address both scientific complexity and global treatment inequity in cancer care. By integrating research, clinical trials and commercialization, BeOne helps reduce the time required to bring therapies to market. Its global approach ensures that innovative treatments are not limited to specific regions, supporting broader access to life-saving oncology medicines.
